Efficacy and safety of an anti-CD20 monoclonal antibody (Reditux™) for the treatment of patients with moderate to severe rheumatoid arthritis following the failure of conventional synthetic disease-modifying anti-rheumatic drugs

被引:7
作者
Bhati, Manjeet [1 ]
Bandyopadhyay, Syamasis [1 ,2 ]
机构
[1] Apollo Gleneagles Hosp, 58 Canal Circular Rd, Kolkata 700054, W Bengal, India
[2] 101-A Jodhpur Pk, Kolkata 700068, W Bengal, India
关键词
Biologic treatment; DMARDs; Reditux (TM); Rheumatoid arthritis; Rituximab; EULAR RECOMMENDATIONS; INADEQUATE RESPONSE; DOUBLE-BLIND; RITUXIMAB; THERAPY; METHOTREXATE; GUIDELINES; MANAGEMENT; INHIBITOR; TRIAL;
D O I
10.1007/s10067-016-3332-8
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Rituximab (anti-CD20 monoclonal antibody) has shown to improve symptoms in rheumatoid arthritis (RA) patients with inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs). An anti-CD20 monoclonal antibody (Reditux (TM)) developed by Dr. Reddy's Laboratories, India, is currently approved for use both in rheumatology and oncology patients. This retrospective report evaluates the efficacy and safety data from the real-world use of Reditux (TM) over a 6-month period in Indian patients with RA. All consecutive moderate to severe RA patients who failed therapy with at least two DMARDs including methotrexate (MTX) for 6 months, TNF alpha inhibitor naive, and willing to take Reditux (TM) were included. They were prescribed two doses of 1 g Reditux (TM), at least 15 days apart, with continued stable doses of methotrexate. Efficacy and safety after 24 weeks relative to baseline was assessed using various health assessment variables. A total of 39 patients (mean age of 46 years; 67.5 % females) treated with Reditux (TM) were evaluated. Statistically significant differences were observed in mean changes of DAS28-CRP, DAS28-ESR, SDAI, HAQ and Patient Global Assessment scores from baseline to 24 weeks (p < 0.0001 for all). Average steroid use per week also significantly reduced at 24 weeks (p = 0.0002). There was no significant gender difference. Mean changes in SDAI, HAQ and Patient Global Assessment scores for patients on steroids were significantly different from those not on steroids (p < 0.05 for all). At 24 weeks, 97 % of patients achieved ACR20 response demonstrating the efficacy of Reditux (TM) treatment. The treatment was well tolerated by patients without any clinically relevant serious adverse events over 24 weeks. Though limited by number of patients and retrospective in nature, this analysis serves as a real-world evidence of efficacy and safety of Dr. Reddy's rituximab (Reditux (TM)) in the treatment of csDMARD-failed patients with RA over a 6-month period.
引用
收藏
页码:1931 / 1935
页数:5
相关论文
共 17 条
  • [1] [Anonymous], 2007, DR REDDYS LAUNCHES R
  • [2] Biswas G, 2006, J Assoc Physicians India, V54, P29
  • [3] Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis
    Buch, Maya H.
    Smolen, Josef S.
    Betteridge, Neil
    Breedveld, Ferdinand C.
    Burmester, Gerd
    Doerner, Thomas
    Ferraccioli, Gianfranco
    Gottenberg, Jacques-Eric
    Isaacs, John
    Kvien, Tore K.
    Mariette, Xavier
    Martin-Mola, Emilio
    Pavelka, Karel
    Tak, Paul P.
    van der Heijde, Desiree
    van Vollenhoven, Ronald F.
    Emery, Paul
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2011, 70 (06) : 909 - 920
  • [4] BSR and BHPR guidelines on the use of rituximab in rheumatoid arthritis
    Bukhari, Marwan
    Abernethy, Rikki
    Deighton, Chris
    Ding, Tina
    Hyrich, Kimme
    Lunt, Mark
    Luqmani, Raashid
    Kiely, Patrick
    Bosworth, Ailsa
    Ledingham, Jo
    Oestoer, Andrew
    Gadsby, Kate
    McKenna, Frank
    Finney, Diana
    Dixey, Josh
    [J]. RHEUMATOLOGY, 2011, 50 (12) : 2311 - 2313
  • [5] Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy - Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks
    Cohen, Stanley B.
    Emery, Paul
    Greenwald, Maria W.
    Dougados, Maxime
    Furie, Richard A.
    Genovese, Mark C.
    Keystone, Edward C.
    Loveless, James E.
    Burmester, Gerd-Ruediger
    Cravets, Matthew W.
    Hessey, Eva W.
    Shaw, Timothy
    Totoritis, Mark C.
    [J]. ARTHRITIS AND RHEUMATISM, 2006, 54 (09): : 2793 - 2806
  • [6] Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis
    Edwards, JCW
    Szczepanski, L
    Szechinski, J
    Filipowicz-Sosnowska, A
    Emery, P
    Close, DR
    Stevens, RM
    Shaw, T
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (25) : 2572 - 2581
  • [7] The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment - Results of a phase IIb randomized, double-blind, placebo-controlled, dose-ranging trial
    Emery, P
    Fleischmann, R
    Filipowicz-Sosnowska, A
    Schechtman, J
    Szczepanski, L
    Kavanaugh, A
    Racewicz, AJ
    Van Vollenhoven, RF
    Li, NF
    Agarwal, S
    Hessey, EW
    Shaw, TM
    [J]. ARTHRITIS AND RHEUMATISM, 2006, 54 (05): : 1390 - 1400
  • [8] Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naive with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab's Efficacy in MTX iNadequate rEsponders (SERENE))
    Emery, P.
    Deodhar, A.
    Rigby, W. F.
    Isaacs, J. D.
    Combe, B.
    Racewicz, A. J.
    Latinis, K.
    Abud-Mendoza, C.
    Szczepanski, L. J.
    Roschmann, R. A.
    Chen, A.
    Armstrong, G. K.
    Douglass, W.
    Tyrrell, H.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2010, 69 (09) : 1629 - 1635
  • [9] Safety and Effectiveness of Rituximab in Patients with Rheumatoid Arthritis Following an Inadequate Response to 1 Prior Tumor Necrosis Factor Inhibitor: The RESET Trial
    Haraoui, Boulos
    Bokarewa, Maria
    Kallmeyer, Ian
    Bykerk, Vivian P.
    [J]. JOURNAL OF RHEUMATOLOGY, 2011, 38 (12) : 2548 - 2556
  • [10] The updated guidelines on the use of rituximab in rheumatoid arthritis
    Lopez-Olivo, Maria A.
    Tayar, Jean H.
    Suarez-Almazor, Maria E.
    [J]. RHEUMATOLOGY, 2011, 50 (12) : 2153 - 2154